European generic prescribing trends and biosimilars

Generics/Research | Posted 29/07/2009 post-comment0 Post your comment

Pressure to control pharmaceutical expenditure and price competition among pharmaceutical companies is fuelling the development of generic medicines markets in ambulatory care in Europe.

Professor Steven Simoens of the Katholieke Universiteit Leuven in Belgium wrote a special report aiming to identify, interpret and discuss the main supply and demand trends affecting the European generic medicines market in ambulatory care.

 

On the supply side, generic price-regulated systems and reference pricing systems are spreading across Europe.

 

On the demand side, European countries have attempted to stimulate demand for generic medicines by focusing on physician prescribing, generic substitution by pharmacists and patient copayments.

 

Finally, the development of biosimilars will probably become an important area of growth for the pharmaceutical industry over the next five years.

Source: Expert Rev Clin Pharmacol. 2008;1(4):497-503.

comment icon Comments (0)
Post your comment
Related content
Pricing and reimbursement of medicines in Canada
79 MD002389
Generics/Research Posted 02/09/2022
Relevance of NTI to the treatment of epilepsy
Epileptic V16F10
Generics/Research Posted 01/07/2022
What is the meaning of a narrow therapeutic index?
05 AA011027
Generics/Research Posted 17/06/2022
Most viewed articles
About GaBI
Home/About GaBI Posted 06/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010